Comparison of the injection‐site experience of semaglutide in a single‐dose and a multidose pen‐injector

Snitker, Søren; Andersen, Andreas; Lindskov, Pernille Skøtt; Marle, Sjoerd van; Sode, Birgitte F.; Sparre, Thomas

doi:10.1111/dom.14718

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used 29G needles for drug delivery in the semaglutide and dulaglutide therapy groups. A single-dose pen-injector (SPI) for semaglutide therapy is approved and used for patients with T2DM in Japan, whereas a multidose pen-injector (MPI) is used in other countries [ 42 ]. The mean visual analog scale score for pain intensity at the injection site has been reported to be higher with the SPI than with the MPI [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study

Omachi,

Ohara,

Fujikawa

et al. 2023

Diabetes Ther

View full text Add to dashboard Cite

Introduction Recent trials have shown that glucagon-like peptide-1 receptor agonists considerably reduce atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Oxidative stress, a surrogate marker of cardiovascular risk, is associated with glucose variability. However, to the best of our knowledge, no studies have compared the effects of injectable semaglutide and dulaglutide therapies on oxidative stress and glucose variability assessed via continuous glucose monitoring (CGM). This study aimed to analyze and compare the effects of semaglutide and dulaglutide therapies on oxidative stress and glucose variability as assessed through CGM. Methods This is an open-label, multicenter, randomized, prospective, parallel-group comparison study. Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy ( n = 19) and one receiving injectable semaglutide therapy ( n = 18) groups. The coprimary endpoints were changes in the results of the diacron-reactive oxygen metabolites test, an oxidative stress marker, and CGM-evaluated glucose variability after 24 weeks. The secondary endpoint was changes in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores. Results Switching to semaglutide therapy was better than continuous dulaglutide therapy in reducing oxidative stress, glucose variability, and glycated hemoglobin levels. Conversely, continuous dulaglutide therapy was better than semaglutide therapy in terms of DTSQ scores for “Convenience” and “Recommend.” Conclusion Injectable semaglutide therapy may be more effective than dulaglutide therapy in ameliorating oxidative stress and regulating glucose metabolism, including glucose variability, in patients with T2DM, while dulaglutide therapy may be more effective in terms of treatment satisfaction. Clinical Trial Registration UMIN-CRT ID: UMIN000042670 (registered 7 December 2020).

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study

Omachi,

Ohara,

Fujikawa

et al. 2023

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…With regard to injection pain and discomfort, most participants disagreed that using the pen was painful, and agreed the pen did not cause discomfort and was less painful than expected. In a previous double‐blind comparison of the SPI and MPI, most participants rated injection‐site pain as ‘none’ or ‘mild’ with both products 11 . The MPI has also been compared with dulaglutide injection 12 .…”

Section: Discussionmentioning

confidence: 99%

“…In a previous double‐blind comparison of the SPI and MPI, most participants rated injection‐site pain as ‘none’ or ‘mild’ with both products. 11 The MPI has also been compared with dulaglutide injection. 12 While semaglutide 2.4 mg is to be stored in the refrigerator, its instructions for use do not preclude allowing it to warm up to room temperature prior to injection.…”

Section: Discussionmentioning

confidence: 99%

Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial

Snitker

Egebjerg

Frederiksen

et al. 2022

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite